Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
1980 1
1981 2
1982 3
1985 2
1986 2
1992 1
1993 1
1994 3
1995 3
1996 1
1997 1
1998 1
2000 1
2001 2
2004 5
2007 1
2008 1
2009 3
2010 2
2011 3
2012 2
2013 2
2015 1
2016 3
2018 2
2019 1
2020 2
2021 4
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
Mitoquinone mesylate attenuates pathological features of lean and obese allergic asthma in mice.
Chandrasekaran R, Bruno SR, Mark ZF, Walzer J, Caffry S, Gold C, Kumar A, Chamberlain N, Butzirus IM, Morris CR, Daphtary N, Aliyeva M, Lam YW, van der Vliet A, Janssen-Heininger Y, Poynter ME, Dixon AE, Anathy V. Chandrasekaran R, et al. Among authors: mark zf. Am J Physiol Lung Cell Mol Physiol. 2023 Feb 1;324(2):L141-L153. doi: 10.1152/ajplung.00249.2022. Epub 2022 Dec 13. Am J Physiol Lung Cell Mol Physiol. 2023. PMID: 36511516 Free PMC article.
MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
Kanagasabai T, Li G, Shen TH, Gladoun N, Castillo-Martin M, Celada SI, Xie Y, Brown LK, Mark ZA, Ochieng J, Ballard BR, Cordon-Cardo C, Adunyah SE, Jin R, Matusik RJ, Chen Z. Kanagasabai T, et al. Among authors: mark za. Cancer Lett. 2022 Jan 28;525:46-54. doi: 10.1016/j.canlet.2021.09.041. Epub 2021 Oct 2. Cancer Lett. 2022. PMID: 34610416
Inhibition of PDIA3 in club cells attenuates osteopontin production and lung fibrosis.
Kumar A, Elko E, Bruno SR, Mark ZF, Chamberlain N, Mihavics BK, Chandrasekaran R, Walzer J, Ruban M, Gold C, Lam YW, Ghandikota S, Jegga AG, Gomez JL, Janssen-Heininger YM, Anathy V. Kumar A, et al. Among authors: mark zf. Thorax. 2022 Jul;77(7):669-678. doi: 10.1136/thoraxjnl-2021-216882. Epub 2021 Aug 16. Thorax. 2022. PMID: 34400514 Free PMC article.
DRP1-Mediated Mitochondrial Fission Regulates Lung Epithelial Response to Allergen.
Bruno SR, Kumar A, Mark ZF, Chandrasekaran R, Nakada E, Chamberlain N, Mihavics B, Walzer J, Cahoon J, Dixon AE, Cunniff B, Anathy V. Bruno SR, et al. Among authors: mark zf. Int J Mol Sci. 2021 Oct 15;22(20):11125. doi: 10.3390/ijms222011125. Int J Mol Sci. 2021. PMID: 34681784 Free PMC article.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Garassino MC, et al. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12. Lancet Oncol. 2018. PMID: 29545095 Free PMC article. Clinical Trial.
62 results